Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triptorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 3/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.66 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.59 |
| ▸ | APLNR | P35414 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triptorelin SCHEMBL16815056 | 1.00 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL1371630 | 1.00 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL22289009 | 1.00 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL1652722 | 1.00 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| SCHEMBL11678163 | 0.99 | PTGS1 (0.73) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL29459903 | 0.99 | PTGS1 (0.72) | PTGS1GNRHRABCC2C5AR1APLNR | |
| SCHEMBL29373920 | 0.98 | PTGS1 (0.72) | PTGS1GNRHRABCC2C5AR1CXCR4 | |
| SCHEMBL29914777 | 0.98 | PTGS1 (0.72) | PTGS1GNRHRABCC2C5AR1APLNR | |
| SCHEMBL1319486 | 0.98 | PTGS1 (0.71) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Gonadorelin SCHEMBL143114 | 0.98 | PTGS1 (0.71) | PTGS1GNRHRABCC2C5AR1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4010125-A | [D-Trp6 ]-LH-RH and intermediates therefor | SCHALLY ANDREW VICTOR | 1977-03-01 | — | — | US | claimed |
| WO-2013083605-A1 | TRIPTORELIN PHARMACEUTICAL COMPOSITION | FERRING BV (NL) | 2013-06-13 | — | — | WO | disclosed |
| EP-1104296-B1 | BIOIMPLANT FORMULATION | PEPTECH ANIMAL HEALTH PTY LTD (AU) | 2012-06-13 | — | — | EP | disclosed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20050276854-A1 | Bioimplant formulation | PEPTECH LIMITED (AU) | 2005-12-15 | — | — | US | disclosed |
| US-6913761-B1 | Bioimplant formulation | PEPTECH LIMITED (AU) | 2005-07-05 | — | — | US | disclosed |
| EP-1104296-A4 | BIOIMPLANT FORMULATION | PEPTECH LTD (AU) | 2004-11-10 | — | — | EP | disclosed |
| US-6777386-B2 | PEPTIDE AGONIST OR ANALOGUE OTHER THAN DESLORELIN; LECITHIN AND STEARIN; PREFERABLY COMPRISES A GNRH AGONIST AND IS USED FOR THE TREATMENT OF VARIOUS CONDITIONS WHERE SUPPRESSION OF SEX HORMONE LEVELS IS BENEFICIAL | PEPTECH LIMITED (AU) | 2004-08-17 | — | — | US | disclosed |
| US-20020052320-A1 | Sustained peptide-release formulation | PEPTECH LIMITED | 2002-05-02 | — | — | US | disclosed |
| EP-1104296-A1 | BIOIMPLANT FORMULATION | PEPTECH LIMITED (AU) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000004897-A1 | BIOIMPLANT FORMULATION | PEPTECH LIMITED (AU) | 2000-02-03 | — | — | WO | disclosed |
| US-4301066-A | Preparation of (D-Trp 6)-LH-RH via the heptapeptide H-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2 | AMERICAN HOME PRODUCTS CORP. (US) | 1981-11-17 | — | — | US | disclosed |
| US-4010125-A | [D-Trp6 ]-LH-RH and intermediates therefor | SCHALLY ANDREW VICTOR | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | GNRHR 1/4885PTGS1 2436/4885ABCC2 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.